Target intelligence / Profile preview

Myelin and lymphocyte protein (MAL)

Target
MAL
Molecular classification
Integral membrane protein, Proteolipid, Tetraspan integral membrane protein, MARVEL (MAL and related proteins for vesicle trafficking and membrane link) domain family
01

Overview

Myelin and lymphocyte protein (MAL) is a highly hydrophobic, tetraspan integral membrane proteolipid that localizes to specialized membrane domains in T cells, polarized epithelial cells, and myelin-forming cells[1][2][4][5]. It is a member of the MARVEL domain family, involved in organizing and maintaining membrane microdomains important for vesicular trafficking, signal transduction, and myelin sheath maintenance[1][2]. In T cells, MAL is crucial for trafficking of key signaling molecules such as Lck kinase and is upregulated during Th2 differentiation in inflammatory or allergic responses[1]. In myelinating cells, it regulates lateral diffusion and membrane organization important for compact myelin formation and stability[1][5]. Its downregulation or epigenetic silencing is observed in various carcinomas, supporting a tumor suppressor role, while it also serves as a marker for primary mediastinal large B-cell lymphoma[3]. Although proposed as a receptor for Clostridium perfringens epsilon toxin, its prevailing biological roles are in membrane specialization and immune or neural development[1][2][5].

Other names
T-lymphocyte maturation-associated proteinMVP17VIP17HLD28malT-cell differentiation proteinT cell differentiation proteinmyelin and lymphocyte proteinplasmolipin-like protein 1BENE
02

Biological functions

Membrane traffickingMyelin sheath maintenanceT cell signal transductionApical protein sortingExosome biogenesisStabilization and maintenance of glycosphingolipid-enriched membrane microdomains
03

Disease associations

Cancer (tumor suppressor—particularly in carcinoma and lymphomas)Neurological/myelin disordersAtopic/inflammatory diseasePrimary mediastinal large B-cell lymphoma
04

Safety considerations

Loss in expression may be associated with tumor progression, but no specific drug safety concerns reported
05

Biomarkers

Primary mediastinal large B-cell lymphoma (diagnostic biomarker)Epigenetic loss can serve as biomarker in carcinomas

Beyond the preview

Go deeper on Myelin and lymphocyte protein (MAL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myelin and lymphocyte protein (MAL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call